 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Daniel J. Haraf and Philip Charles Hoffman.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.448 |
|
|
|
-
Hoffman PC, Cohen EE, Masters GA, Haraf DJ, Mauer AM, Rudin CM, Krauss SA, Huo D, Vokes EE. Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung Cancer. 2002 Oct; 38(1):65-71.
Score: 0.064
-
Hoffman PC, Haraf DJ, Ferguson MK, Drinkard LC, Vokes EE. Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: a long-term analysis. Ann Oncol. 1998 Jun; 9(6):647-51.
Score: 0.047
-
Vokes EE, Mauer AM, Hoffman PC, Haraf DJ. Combined modality therapy in non-small cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy. Semin Oncol. 1998 Jun; 25(3 Suppl 8):28-32.
Score: 0.047
-
Vokes EE, Haraf DJ, Hoffman PC. Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study. Cancer Chemother Pharmacol. 1993; 33(3):203-9.
Score: 0.032
-
Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
Score: 0.030
-
Shumway D, Corbin K, Salgia R, Hoffman P, Villaflor V, Malik RM, Haraf DJ, Vigneswaren WT, Shaikh AY, Connell PP, Ferguson MK, Salama JK. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):446-50.
Score: 0.029
-
Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
Score: 0.024
-
Choong NW, Vokes EE, Haraf DJ, Tothy PK, Ferguson MK, Kasza K, Rudin CM, Hoffman PC, Krauss SA, Szeto L, Mauer AM. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol. 2008 Jan; 3(1):59-67.
Score: 0.023
-
Shaikh AY, Haraf DJ, Salama JK, Salgia R, Hoffman PC, Ferguson MK, Connell PP. Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. Am J Clin Oncol. 2007 Jun; 30(3):258-63.
Score: 0.022
-
Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):515-22.
Score: 0.021
-
George CM, Haraf DJ, Mauer AM, Krauss SA, Hoffman PC, Rudin CM, Szeto L, Vokes EE. A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. Invest New Drugs. 2001; 19(4):303-10.
Score: 0.014
-
Ferguson MK, Wang J, Hoffman PC, Haraf DJ, Olak J, Masters GA, Vokes EE. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg. 2000 Jan; 69(1):245-9; discussion 249-50.
Score: 0.013
-
Masters GA, Haraf DJ, Hoffman PC, Drinkard LC, Krauss SA, Ferguson MK, Olak J, Samuels BL, Golomb HM, Vokes EE. Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol. 1998 Jun; 16(6):2157-63.
Score: 0.012
-
Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM, Vokes EE. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 1998 Jan; 16(1):159-64.
Score: 0.011
-
Vokes EE, Masters GA, Mauer AM, Haraf DJ, Hoffman PC, Golomb HM. Clinical studies of docetaxel (Taxotere) and concomitant chest therapy. Semin Oncol. 1997 Aug; 24(4 Suppl 14):S14-26-S14-29.
Score: 0.011
-
Vokes EE, Haraf DJ, Masters GA, Hoffman PC, Drinkard LC, Ferguson M, Olak J, Watson S, Golomb HM. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study. Semin Oncol. 1996 Apr; 23(2 Suppl 5):48-52.
Score: 0.010
-
Ferguson MK, Reeder LB, Hoffman PC, Haraf DJ, Drinkard LC, Vokes EE. Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol. 1995 Mar; 2(2):101-6.
Score: 0.009
-
Vokes EE, Haraf DJ, Drinkard LC, Hoffman PC, Ferguson MK, Vogelzang NJ, Watson S, Lane NJ, Golomb HM. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. Cancer Chemother Pharmacol. 1995; 35(4):304-12.
Score: 0.009
-
Vokes EE, Drinkard LC, Samuels BL, Hoffman PC, Watson S, Bitran JD, Haraf DJ, Ferguson MF, Golomb HM. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design. Semin Oncol. 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4.
Score: 0.009
-
Vokes EE, Haraf DJ, Hoffman PC, Bitran JD, Ferguson MK, Golomb HM. Concomitant chemoradiotherapy for non-small cell lung cancer. Lung Cancer. 1994 Mar; 10 Suppl 1:S253-61.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|